ArticleBMC urology2026
Evolution of treatment and oncological outcomes in patients undergoing radical cystectomy: a comparative analysis across two decades at a tertiary center.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the last two decades, significant advances in the perioperative management of muscle-invasive bladder cancer, such as enhanced recovery protocols, increased use of neoadjuvant chemotherapy, improved care pathways, and stronger multidisciplinary collaboration, have reshaped surgical outcomes. This study aimed to evaluate the evolution of care and oncological outcomes in patients undergoing radical cystectomy at a Brazilian tertiary cancer center over 20 years.
methodsWe retrospectively analyzed clinical, surgical, and pathological data from patients with bladder cancer who underwent radical cystectomy between January 2005 and April 2025. Patients were stratified into two cohorts according to the year of surgery (2005-2014 vs. 2015-2025). Survival analyses were performed using Kaplan-Meier curves to compare overall survival, cancer-specific survival, and recurrence-free survival between periods.
resultsA total of 733 patients were included (mean age, 66.2 years; 69.2% male). An age-adjusted Charlson Comorbidity Index ≥ 3 was present in 90.4%, and preoperative hydronephrosis in 41.5%. Locally advanced disease (pT3-pT4) occurred in 50.9%, lymph node positivity (pN+) in 26.6%, and 34.5% received neoadjuvant chemotherapy. Early complications (< 30 days) occurred in 51.2%, early reoperation in 19.3%, and late complications (30-90 days) in 24.0%, with 33.3% classified as Clavien-Dindo grade ≥ III. On multivariable Cox regression, treatment period remained independently associated with improved overall survival (HR 0.75, 95% CI 0.58-0.97; p = 0.029). Clinical stage was also independently associated with overall survival (overall p = 0.046), with advanced stage increasing the hazard of death (HR 1.48, 95% CI 1.08-2.02; p = 0.015). Kaplan-Meier analysis showed significantly improved overall, cancer-specific, and recurrence-free survival in 2015-2025 versus 2005-2014 (all log-rank p < 0.001).
conclusionImproved survival after radical cystectomy over the last decade reflects advances in perioperative care in the management of bladder cancer patients undergoing radical cystectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.